ISSN 1725-2423

Official Journal of the European Union

C 39

Volume 50

English edition

Information and Notices

23 February 2007

Contents

EN

[1] Text with EEA relevance

(Continued overleaf)

EN

([1]) Text with EEA relevance

I

(Resolutions, recommendations, guidelines and opinions)

OPINIONS

EUROPEAN CENTRAL BANK

OPINION OF THE EUROPEAN CENTRAL BANK

of 15 February 2007

at the request of the Council of the European Union on eight proposals amending Directives 2006/49/EC, 2006/48/EC, 2005/60/EC, 2004/109/EC, 2004/39/EC, 2003/71/EC, 2003/6/EC and 2002/87/EC, as regards the implementing powers conferred on the Commission

(CON/2007/4)

(2007/C 39/01)

Introduction and legal basis

On 29 and 31 January 2007 the European Central Bank (ECB) received requests from the Council of the European Union for an opinion on eight proposals for directives [1] in the financial field (hereinafter 'the proposals') whose main objectives are to amend the comitology provisions of eight existing directives to incorporate provisions on a new comitology procedure (the 'regulatory procedure with scrutiny'), following the adoption of Council Decision 2006/512/EC of 17 July 2006 amending Decision 1999/468/EC laying down the procedures for the exercise of implementing powers conferred on the Commission [2], and to repeal the provisions of the eight existing directives that provide for a time limit for the delegation of implementing powers to the Commission (the so-called 'sunset clauses'). The ECB's competence to deliver an opinion is based on Article 105(4) of the Treaty establishing the European Community. In accordance with the first sentence of Article 17(5) of the Rules of Procedure of the European Central Bank, the Governing Council has adopted this opinion.

1. Observations

1.1 The ECB welcomes the new agreement on comitology reached between the European Parliament, the Council and the Commission, which is of great importance for the continued functioning of the Lamfalussy process.

---

[1] (1) Proposal for a Directive of the European Parliament and of the Council amending Directive 2006/49/EC on the capital adequacy of investment firms and credit institutions, as regards the implementing powers conferred on the Commission (COM(2006) 90l final); (2) Proposal for a Directive of the European Parliament and of the Council amending Directive 2006/48/EC relating to the taking up and pursuit of the business of credit institutions, as regards the implementing powers conferred to the Commission (COM(2006) 902 final); (3) Proposal for a Directive of the European Parliament and of the Council amending Directive 2005/60/EC on the prevention of the use of the financial system for the purpose of money laundering and terrorist financing, as regards the implementing powers conferred on the Commission (COM(2006) 906 final); (4) Proposal for a Directive of the European Parliament and of the Council amending Directive 2004/109/EC relating to the harmonisation of transparency requirements in relation to information about issuers whose securities are admitted to trading on a regulated market as regards the implementing powers conferred on the Commission (COM(2006) 909 final); (5) Proposal for a Directive of the European Parliament and of the Council amending Directive 2004/39/EC relating to markets in financial instruments as regards the implementing powers conferred on the Commission (COM(2006) 910 final); (6) Proposal for a Directive of the European Parliament and of the Council amending Directive 2003/71/EC relating to the prospectus to be published when securities are offered to the public or admitted to trading, as regards the implementing powers conferred on the Commission (COM(2006) 911 final); (7) Proposal for a Directive of the European Parliament and of the Council amending Directive 2003/6/EC on insider dealing and market manipulation (market abuse), as regards the implementing powers conferred on the Commission (COM(2006) 913 final); (8) Proposal for a Directive of the European Parliament and of the Council amending Directive 2002/87/EC relating to the supplementary supervision of credit institutions, insurance undertakings and investment firms in a financial conglomerate as regards the implementing powers conferred on the Commission (COM(2006) 916 final).

[2] OJ L 200, 22.7.2006, p. 11.

1.2 The ECB has no specific comments on the proposals which are in line with the joint statement of the European Parliament, the Council and the Commission on the introduction of the new 'regulatory procedure with scrutiny' into the comitology framework ([3]).

1.3 Having regard to the importance of the role played by implementing measures in EU legislation in the financial services field, the ECB takes this opportunity to underline the importance of its advisory role under Article 105(4) of the Treaty, which requires the ECB to be consulted 'on any proposed Community act in its fields of competence'. As recently noted ([4]), 'the ECB considers that proposed Level 2 acts constitute "proposed Community acts" within the meaning of Article 105(4) of the Treaty' ([5]). Therefore the Treaty provision which requires the ECB to be consulted on any proposed Community act in its field of competence includes an obligation for it to be consulted on these implementing acts ([6]).

Done at Frankfurt am Main, 15 February 2007.

The President of the ECB
Jean-Claude TRICHET

([3]) Statement by the European Parliament, the Council and the Commission concerning the Council Decision of 17 July 2006 amending Decision 1999/468/EC laying down the procedures for the exercise of implementing powers conferred on the Commission (2006/512/EC), (OJ C 255, 21.10.2006, p. 1).

([4]) ECB Opinion CON/2006/57 of 12 December 2006 on a draft Commission Directive implementing Council Directive 85/611/EEC on the coordination of laws, regulations and administrative provisions relating to undertakings for collective investment in transferable securities (UCITS) as regards the clarification of certain definitions.

([5]) Under the Lamfalussy framework the implementing acts are referred as 'Level 2 acts'.

([6]) The lack of consultation between Community institutions has been the subject of several judgments by the Court of Justice. On the obligation to consult the European Parliament, see Case 138/79 *Roquette Frères* [1980] ECR 3333 and Case C-21/94 *Parliament* v *Council* [1995] ECR I-1827, paragraph 17. On the obligation of the High Authority to consult the Council and the Consultative Committee under the ECSC Treaty, see Case 1/54 *France* v *High Authority* [1954-56] ECR 1, at p 15 and Case 2/54 *Italy* v *High Authority* [1954-56] ECR 37, at p 52, which was confirmed by Case 6/54 *Netherlands* v *High Authority* [1954-56] ECR 103, at p 112. As far as Article 105(4) of the Treaty is concerned, in Case C-11/00 *Commission* v *European Central Bank* [2003] ECR I-7147, Advocate General Jacobs emphasised that: 'Consultation of the ECB on proposed measures in its field of competence is a procedural step, required by a provision of the Treaty, which is clearly capable of affecting the content of the measures adopted. Failure to comply with such requirement must, in my view, be capable of leading to the annulment of the measures adopted', Opinion of Advocate General Jacobs given on 3 October 2002, paragraph 131.

II

(Information)

INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES

COMMISSION

Non-opposition to a notified concentration

(Case COMP/M.4445 — voestalpine/Stamptec)

(Text with EEA relevance)

(2007/C 39/02)

On 6 February 2007, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website under document number 32007M4445. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu)

Non-opposition to a notified concentration

(Case COMP/M.4431 — BG Group/Serene)

(Text with EEA relevance)

(2007/C 39/03)

On 1 February 2007, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website under document number 32007M4431. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu)

Non-opposition to a notified concentration

(Case COMP/M.4510 — L Capital 2/Calligaris)

(Text with EEA relevance)

(2007/C 39/04)

On 12 February 2007, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website under document number 32007M4510. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu)

Non-opposition to a notified concentration

(Case COMP/M.4319 — Mondi/Schleipen & Erkens)

(Text with EEA relevance)

(2007/C 39/05)

On 24 October 2006, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website under document number 32006M4319. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu)

Non-opposition to a notified concentration

(Case COMP/M.4314 — Johnson & Johnson/Pfizer Consumer Healthcare)

(Text with EEA relevance)

(2007/C 39/06)

On 11 December 2006, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(2) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website under document number 32006M4314. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu)

Non-opposition to a notified concentration

(Case COMP/M.4526 — PAI/Lafarge)

(Text with EEA relevance)

(2007/C 39/07)

On 15 February 2007, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website under document number 32007M4526. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu)

IV

(Notices)

NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES

COMMISSION

Euro exchange rates ([1])

22 February 2007

(2007/C 39/08)

1 euro =

	Currency	Exchange rate		Currency	Exchange rate
USD	US dollar	1,3106	RON	Romanian leu	3,3815
JPY	Japanese yen	159,00	SKK	Slovak koruna	34,286
DKK	Danish krone	7,4555	TRY	Turkish lira	1,8110
GBP	Pound sterling	0,67190	AUD	Australian dollar	1,6610
SEK	Swedish krona	9,3155	CAD	Canadian dollar	1,5214
CHF	Swiss franc	1,6281	HKD	Hong Kong dollar	10,2376
ISK	Iceland króna	87,15	NZD	New Zealand dollar	1,8560
NOK	Norwegian krone	8,0635	SGD	Singapore dollar	2,0108
BGN	Bulgarian lev	1,9558	KRW	South Korean won	1 230,52
CYP	Cyprus pound	0,5792	ZAR	South African rand	9,2551
CZK	Czech koruna	28,237	CNY	Chinese yuan renminbi	10,1475
EEK	Estonian kroon	15,6466	HRK	Croatian kuna	7,3433
HUF	Hungarian forint	251,67	IDR	Indonesian rupiah	11 900,90
LTL	Lithuanian litas	3,4528	MYR	Malaysian ringgit	4,5805
LVL	Latvian lats	0,7057	PHP	Philippine peso	63,302
MTL	Maltese lira	0,4293	RUB	Russian rouble	34,3900
PLN	Polish zloty	3,8762	THB	Thai baht	44,460

([1]) *Source:* reference exchange rate published by the ECB.

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 January 2007 to 31 January 2007

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council ([1]))

(2007/C 39/09)

— Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorization	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
4.1.2007	ADROVANCE	Alendronate sodium/Colecalciferol	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	EU/1/06/364/001-005	Tablet	(Non applicable)	9.1.2007
4.1.2007	Diacomit	Stiripentol	Biocodex 7, avenue Gallieni F-94250 Gentilly	EU/1/06/367/001-006 EU/1/06/367/007-012	Capsule Powder for oral suspension	N03AX17	9.1.2007
8.1.2007	Elaprase	Idursulfase	Shire Human Genetic Therapies AB Rinkebyvägen 11B SE-182 36 Danderyd	EU/1/06/365/001-003	Concentrate for solution for infusion	A16AB09	10.1.2007
8.1.2007	Tandemact	Pioglitazone/Glimepiride	Takeda Global Research and Development Centre (Europe) Ltd Arundel Great Court 2 Arundel Street London WC2R 3DA United Kingdom	EU/1/06/366/001-004	Tablet	(Non applicable)	10.1.2007
16.1.2007	Inovelon	rufinamide	Eisai Limited 3, Shortlands London W6 8EE United Kingdom	EU/1/06/378/001-016	Film-coated tablet	N03AF03	18.1.2007
16.1.2007	Dafiro	amlodipine/valsartan	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/06/371/001-024	Film-coated tablet	C09DB01	18.1.2007

([1]) OJ L 136, 30.4.2004, p. 1.

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorization	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
16.1.2007	Copalia	amlodipine/valsartan	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/06/372/001-024	Film-coated tablet	C09DB01	18.1.2007
17.1.2007	Exforge	amlodipine/valsartan	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/06/370/001-024	Film-coated tablet	C09DB01	19.1.2007
17.1.2007	Imprida	amlodipine/valsartan	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/06/373/001-024	Film-coated tablet	C09DB01	19.1.2007
17.1.2007	Insulin Human Winthrop	insulin human	Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main	EU/1/06/368/001-002 EU/1/06/368/011-015 EU/1/06/368/056-057 EU/1/06/368/003-010 EU/1/06/368/020-024 EU/1/06/368/029-033 EU/1/06/368/038-042 EU/1/06/368/047-051 EU/1/06/368/016-019 EU/1/06/368/025-028 EU/1/06/368/034-037 EU/1/06/368/043-046 EU/1/06/368/052-055	Solution for injection Suspension for injection OptiSet, solution for injection	A10AB01	2.2.2007
19.1.2007	Irbesartan BMS	irbesartan	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UD8 1DH United Kingdom	EU/1/06/375/001-015 EU/1/06/375/016-033	Tablet Film-coated tablets	C09CA04	23.2.2007

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorization	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
19.1.2007	Irbesartan Hydrochloro-thiazide BMS	irbesartan/hydrochlorothia-zide	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UD8 1DH United Kingdom	EU/1/06/369/001-010 EU/1/06/369/011-028	Tablet Film-coated tablets	C09DA04	23.1.2007
19.1.2007	Irbesartan Winthrop	Irbesartan	SANOFI PHARMA BRISTOL MYERS SQUIBB SNC 174, avenue de France F-75013 Paris	EU/1/06/376/001-015 EU/1/06/376/016-033	Tablet Film-coated tablets	C09CA04	23.1.2007
19.1.2007	Irbesartan Hydrochloro-thiazide Winthrop	irbesartan/hydrochlorothia-zide	SANOFI PHARMA BRISTOL MYERS SQUIBB SNC 174, avenue de France F-75013 Paris	EU/1/06/377/001-010 EU/1/06/377/011-028	Tablet Film-coated tablets	C09DA04	23.1.2007
22.1.2007	Lucentis	ranibizumab	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/06/374/001	Solution for injection	S01LA04	24.1.2007

— **Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Rejected**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
16.1.2007	Thymanax	Les Laboratoires Servier 22, rue Garnier F-92200 Neuilly-sur-Seine	—	18.1.2007
16.1.2007	Valdoxan	Les Laboratoires Servier 22, rue Garnier F-92200 Neuilly-sur-Seine	—	18.1.2007

— **Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
3.1.2007	MicardisPlus	Boehringer Ingelheim International GmbH Binger Strasse 173 D-55216 Ingelheim am Rhein	EU/1/02/213/001-016	9.1.2007
3.1.2007	Neulasta	Amgen Europe B.V. Minervum 7061 4817 ZK Breda Nederland	EU/1/02/227/001-003	9.1.2007
3.1.2007	Neupopeg	Dompé Biotec S.p.A. Via San Martino 12 I-20122 Milano	EU/1/02/228/001-003	9.1.2007
3.1.2007	Invirase	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/96/026/001-002	9.1.2007
3.1.2007	Ceprotin	Baxter AG Industriesstrasse 67 A-1220 Vienna	EU/1/01/190/001-002	9.1.2007
3.1.2007	Ambirix	GlaxoSmithKline Biologicals s.a. rue de l'Institut 89 B-1330 Rixensart	EU/1/02/224/ 001-005	9.1.2007
3.1.2007	Velcade	Janssen-Cilag International NV Turnhoutseweg 30 B-2340 Beerse	EU/1/04/274/001	9.1.2007
3.1.2007	Zostavax	Sanofi Pasteur MSD, SNC 8, rue Jonas Salk F-69007 Lyon	EU/1/06/341/001-013	9.1.2007
3.1.2007	Nexavar	Bayer HealthCare AG D-51368 Leverkusen	EU/1/06/342/001	9.1.2007
3.1.2007	Telzir	Glaxo Group Ltd Greenford Road Greenford Middlesex UB6 0NN United Kingdom	EU/1/04/282/001-002	9.1.2007

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
4.1.2007	Twinrix Paediatric	GlaxoSmithKline Biologicals s.a. rue de l'Institut 89 B-1330 Rixensart	EU/1/97/029/001-010	9.1.2007
4.1.2007	NovoSeven	Novo Nordisk A/S Novo Allé DK-2880 Bagsværd	EU/1/96/006/001-003	9.1.2007
4.1.2007	PEGASYS	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/02/221/001-010	9.1.2007
4.1.2007	Kinzalmono	Bayer HealthCare AG D-51368 Leverkusen	EU/1/98/091/001-014	9.1.2007
4.1.2007	Twinrix Adult	GlaxoSmithKline Biologicals s.a. rue de l'Institut 89 B-1330 Rixensart	EU/1/96/020/001-009	9.1.2007
4.1.2007	NeoRecormon	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/97/031/001-003 EU/1/97/031/019-046	9.1.2007
4.1.2007	Micardis	Boehringer Ingelheim International GmbH Binger Strasse 173 D-55216 Ingelheim am Rhein	EU/1/98/090/001-020	9.1.2007
4.1.2007	Rebetol	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles Stallestraat 73 B-1180 Brussel	EU/1/99/107/001-005	9.1.2007
4.1.2007	Competact	Takeda Global Research and Development Centre (Europe) Ltd Arundel Great Court 2 Arundel Street London WC2R 3DA United Kingdom	EU/1/06/354/001-009	9.1.2007
4.1.2007	Remicade	Centocor B.V. Einsteinweg 101 2333 CB Leiden Nederland	EU/1/99/116/001-003	9.1.2007
4.1.2007	Ketek	Aventis Pharma S.A. 20, Avenue Raymond Aron F-92160 Antony	EU/1/01/191/001-005	9.1.2007
4.1.2007	Levviax	Aventis Pharma S.A. 20, Avenue Raymond Aron F-92160 Antony	EU/1/01/192/001-005	9.1.2007
4.1.2007	Temodal	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles Stallestraat 73 B-1180 Brussel	EU/1/98/096/001-008	9.1.2007

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
4.1.2007	Keppra	UCB S.A. Allée de la recherche, 60 B-1070 Bruxelles Researchdreef 60 B-1070 Brussel	EU/1/00/146/001-030	10.1.2007
4.1.2007	Kinzalkomb	Bayer HealthCare AG D-51368 Leverkusen	EU/1/02/214/001-010	9.1.2007
8.1.2007	PritorPlus	Bayer HealthCare AG D-51368 Leverkusen	EU/1/02/215/001-014	10.1.2007
8.1.2007	Pritor	Bayer HealthCare AG D-51368 Leverkusen	EU/1/98/089/001-022	10.1.2007
8.1.2007	DepoCyte	SkyePharma PLC 105 Piccadilly London W1J 7NJ United Kindgom	EU/1/01/187/001	10.1.2007
8.1.2007	Agenerase	Glaxo Group Ltd Greenford Middlesex UB6 0NN United Kingdom	EU/1/00/148/001-004	10.1.2007
8.1.2007	IntronA	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles Stallestraat 73 B-1180 Brussel	EU/1/99/127/001-044	10.1.2007
8.1.2007	Viread	Gilead Sciences International Limited Cambridge CB1 6GT United Kingdom	EU/1/01/200/001	10.1.2007
9.1.2007	Puregon	Organon N.V. P.O. Box 20 5340 BH Oss Nederland	EU/1/96/008/001-041	11.1.2007
9.1.2007	Neupro	Schwarz Pharma Ltd Shannon, Industrial Estate Co.Clare Ireland	EU/1/05/331/001-037	11.1.2007
9.1.2007	Viraferon	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles Stallestraat 73 B-1180 Brussel	EU/1/99/128/001-037	11.1.2007
9.1.2007	Thyrogen	Genzyme Europe B.V. Gooimeer 10 1411 DD Naarden Nederland	EU/1/99/122/001-002	11.1.2007
11.1.2007	Karvezide	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UD8 1DH United Kingdom	EU/1/98/085/001-028	15.1.2007
11.1.2007	CoAprovel	Sanofi Pharma Bristol-Myers Squibb SNC 174, avenue de France F-75013 Paris	EU/1/98/086/001-028	15.1.2007

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
11.1.2007	Sutent	Pfizer Ltd Ramsgate Road Sandwich Kent CT 13 9NJ United Kingdom	EU/1/06/347/001-003	15.1.2007
11.1.2007	Viracept	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/97/054/001 EU/1/97/054/003-005	15.1.2007
11.1.2007	Invirase	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/96/026/001-002	15.1.2007
11.1.2007	Karvezide	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UD8 1DH United Kingdom	EU/1/98/085/001-028	15.1.2007
12.1.2007	MabThera	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/98/067/001-002	16.1.2007
12.1.2007	Truvada	Gilead Sciences International Limited Granta Park Abington Cambridge CB1 6GT United Kingdom	EU/1/04/305/001	16.1.2007
12.1.2007	Emtriva	Gilead Sciences International Limited Granta Park Abington Cambridge CB1 6GT United Kingdom	EU/1/03/261/001-003	16.1.2007
12.1.2007	Norvir	Abbott laboratories Ltd Queenborough Kent ME11 5EL United-Kingdom	EU/1/96/016/001 EU/1/96/016/003-004	16.1.2007
15.1.2007	Stocrin	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	EU/1/99/111/001-011	18.1.2007
15.1.2007	Viramune	Boehringer Ingelheim International GmbH Binger Strasse 173 D-55216 Ingelheim am Rhein	EU/1/97/055/001-003	18.1.2007
15.1.2007	Sustiva	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UD8 1DH United Kingdom	EU/1/99/110/001-009	18.1.2007

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
15.1.2007	Viread	Gilead Sciences International Limited Cambridge CB1 6GT United Kingdom	EU/1/01/200/001	18.1.2007
16.1.2007	Insuman	Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main	EU/1/97/030/028-084	2.2.2007
16.1.2007	Kaletra	Abbott Laboratories Ltd Queenborough Kent ME11 5EL United Kingdom	EU/1/01/172/001-005	18.1.2007
17.1.2007	REYATAZ	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/03/267/001-007	19.1.2007
17.1.2007	Revatio	Pfizer Ltd Ramsgate Road Sandwich Kent CT 13 9NJ United Kingdom.	EU/1/05/318/001	19.1.2007
17.1.2007	SUTENT	Pfizer Ltd Ramsgate Road Sandwich Kent CT 13 9NJ United Kingdom	EU/1/06/347/001-003	19.1.2007
17.1.2007	Kivexa	Glaxo Group Ltd Berkeley Avenue Greenford Middlesex UB6 0NN United Kingdom	EU/1/04/298/001-002	19.1.2007
17.1.2007	Lyrica	Pfizer Ltd Ramsgate Road Sandwich Kent CT 13 9NJ United Kingdom	EU/1/04/279/001-035	19.1.2007
17.1.2007	Advate	Baxter AG Industriestraße 67 A-1221 Wien	EU/1/03/271/001-004	19.1.2007
17.1.2007	Ziagen	Glaxo Group Ltd Greenford Middlesex UB6 0NN United Kingdom	EU/1/99/112/001-002	19.1.2007
18.1.2007	Telzir	Glaxo Group Ltd Greenford Middlesex UB6 0NN United Kingdom	EU/1/04/282/001-002	22.1.2007
18.1.2007	Avaglim	SmithKline Beecham plc 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom	EU/1/06/349/001-008	22.1.2007

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
18.1.2007	Enbrel	Wyeth Europa Limited Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH United Kingdom	EU/1/99/126/001-018	22.1.2007
19.1.2007	Zerit	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UD8 1DH United Kingdom	EU/1/96/009/001-009	23.1.2007
24.1.2007	Stalevo	Orion Corporation Orionintie 1 FIN-02200 Espoo	EU/1/03/260/001-015	26.1.2007
24.1.2007	Paxene	Norton Healthcare Limited Albert Basin Royal Docks London E16 2QJ United Kingdom	EU/1/99/113/001-004	26.1.2007
24.1.2007	Comtess	Orion Corporation Orionintie 1 FIN-02200 Espoo	EU/1/98/082/001-003 EU/1/98/082/005	26.1.2007
24.1.2007	Fuzeon	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/03/252/001-003	26.1.2007
24.1.2007	TRIZIVIR	Glaxo Group Ltd Greenford Middlesex UB6 0NN United Kingdom	EU/1/00/156/002-003	26.1.2007
24.1.2007	Agenerase	Glaxo Group Ltd Greenford Middlesex UB6 0NN United Kingdom	EU/1/00/148/001-004	26.1.2007
24.1.2007	Fabrazyme	Genzyme Europe B.V. Gooimeer 10 1411 DD Naarden Nederland	EU/1/01/188/001-006	26.1.2007
24.1.2007	Tarceva	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/05/311/001-003	26.1.2007
24.1.2007	Avandamet	SmithKline Beecham plc 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom	EU/1/03/258/001-022	26.1.2007
24.1.2007	Aptivus	Boehringer Ingelheim International GmbH Binger Strasse 173 D-55216 Ingelheim am Rhein	EU/1/05/315/001	26.1.2007

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
24.1.2007	Nexavar	Bayer HealthCare AG D-51368 Leverkusen	EU/1/06/342/001	26.1.2007
24.1.2007	Crixivan	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU United-Kingdom	EU/1/96/024/001-005 EU/1/96/024/007-008 EU/1/96/024/010	26.1.2007
25.1.2007	Evra	Janssen-Cilag International NV Turnhoutseweg 30 B-2340 Beerse	EU/1/02/223/001-003	29.1.2007
25.1.2007	Epivir	Glaxo Group Ltd Greenford Road Greenford Middlesex UB6 0NN United Kingdom	EU/1/96/015/001-005	29.1.2007
26.1.2007	Alimta	Eli Lilly Nederland B.V. Grootslag 1-5 3991 RA Houten Nederland	EU/1/04/290/001	30.1.2007
26.1.2007	Actos	Takeda Global Research and Development Centre (Europe) Ltd Arundel Great Court 2 Arundel Street London WC2R 3DA United Kingdom	EU/1/00/150/001-024	30.1.2007
26.1.2007	Combivir	Glaxo Group Ltd Greenford Road Greenford Middlesex UB6 0NN United Kingdom	EU/1/98/058/001-002	30.1.2007
26.1.2007	Helixate NexGen	Bayer HealthCare AG D-51368 Leverkusen	EU/1/00/144/001-003	30.1.2007
26.1.2007	TARGRETIN	Ligand Pharmaceuticals UK Ltd Innovis House 108 High Street Crawley West Sussex RH10 1BB United Kingdom	EU/1/01/178/001	30.1.2007
29.1.2007	KOGENATE Bayer	Bayer HealthCare AG D-51368 Leverkusen	EU/1/00/143/001-009	31.1.2007
31.1.2007	Avonex	Biogen Idec Ltd 5 Roxborough Way Foundation Park Maidenhead Berkshire SL6 3UD United Kindgom	EU/1/97/033/001-003	2.2.2007

— **Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted**

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorization	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
9.1.2007	Cortavance	Hydrocortisone aceponate	VIRBAC S.A. 1ère Avenue 2065 m L.I.D F-06516 Carros	EU/2/06/069/001	Cutaneous spray, solution	QD07AC	11.1.2007
11.1.2007	Yposane	Osaterone acetate	VIRBAC S.A. 1ère Avenue 2065 m L.I.D F-06516 Carros	EU/2/06/068/001-004	Tablets	QG04CX	15.1.2007
15.1.2007	Meloxicam CEVA	Meloxicam	CEVA SANTE ANIMALE Z.I. la Ballastière F-33500 Libourne	EU/2/06/070/001-003	oral suspension	QM01AC06	18.1.2007

— **Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
4.1.2007	Previcox	Merial 29, avenue Tony Garnier F-69007 Lyon	EU/2/04/045/001-006	9.1.2007
16.1.2007	Equilis StrepE	Intervet International B.V. Wim de Körverstraat 35 5831 AN Boxmeer Nederland	EU/2/04/043/001	18.1.2007
11.1.2007	Gonazon	Intervet International B.V. Wim de Körverstraat 35 5831 AN Boxmeer Nederland	EU/2/03/040/002	15.1.2007
16.1.2007	Profender	Bayer HealthCare AG D-51368 Leverkusen	EU/2/05/054/001-017	18.1.2007

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency
7, Westferry Circus, Canary Wharf
London E14 4HB
United Kingdom

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 January 2007 to 31 January 2007

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC [1] or Article 38 of Directive 2001/82/EC [2])

(2007/C 39/10)

— Issuing, maintenance or modification of a national marketing authorisation

Date of the decision	Name(s) of the medicinal product	Holder(s) of the marketing authorization	Member State concerned	Date of notification
22.1.2007	Lucentis	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	This Decision is addressed to the Member States	24.1.2007
24.1.2007	Ciprofloxacin Kabi	See Annex I	See Annex I	25.1.2007

[1] OJ L 311, 28.11.2001, p. 67.
[2] OJ L 311, 28.11.2001, p. 1.

ANNEX I

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Name	Strength	Pharmaceutical Form	Route of administration	Content (concentration)
Netherlands	Fresenius Kabi Nederland B.V. Postbus 2379 5202 CJ 's-Hertogenbosch Nederland Tel.: (31) 0800 022 1905 Fax: (31) 0800 022 8295		Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	100 mg/50 ml
Netherlands	Fresenius Kabi Nederland B.V. Postbus 2379 5202 CJ 's-Hertogenbosch Nederland Tel.: (31) 0800 022 1905 Fax: (31) 0800 022 8295		Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml
Netherlands	Fresenius Kabi Nederland B.V. Postbus 2379 5202 CJ 's-Hertogenbosch Nederland Tel.: (31) 0800 022 1905 Fax: (31) 0800 022 8295		Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml
Austria		Fresenius Kabi Austria GmbH Hafnerstraße 36 A-8055 Graz Tel.: (43) 316 24 95 24 Fax: (43) 316 24 92 70	Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	100 mg/50 ml
Austria		Fresenius Kabi Austria GmbH Hafnerstraße 36 A-8055 Graz Tel.: (43) 316 24 95 24 Fax: (43) 316 24 92 70	Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml
Austria		Fresenius Kabi Austria GmbH Hafnerstraße 36 A-8055 Graz Tel.: (43) 316 24 95 24 Fax: (43) 316 24 92 70	Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml

Member State	Marketing Authorisation Holder	Applicant	Name	Strength	Pharmaceutical Form	Route of administration	Content (concentration)
Belgium		Fresenius Kabi N.V. Molenberglei 7 B-2627 Schelle Tel.: (32-3) 880 50 24 Fax: (32-3) 880 28 88	Ciprofloxacin Fresenius Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml
Belgium		Fresenius Kabi N.V. Molenberglei 7 B-2627 Schelle Tel.: (32-3) 880 50 24 Fax: (32-3) 880 28 88	Ciprofloxacin Fresenius Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml
Cyprus		Fresenius Kabi Hellas A.E. 354 Messogion Avenue GR-15341 Agia Paraskevi Attica Tel.: (30) 21 06 54 29 09 Fax: (30) 21 06 54 89 09	Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	100 mg/50 ml
Cyprus		Fresenius Kabi Hellas A.E. 354 Messogion Avenue GR-15341 Agia Paraskevi Attica Tel.: (30) 21 06 54 29 09 Fax: (30) 21 06 54 89 09	Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml
Cyprus		Fresenius Kabi Hellas A.E. 354 Messogion Avenue GR-15341 Agia Paraskevi Attica Tel.: (30) 21 06 54 29 09 Fax: (30) 21 06 54 89 09	Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml
Czech Republic		Fresenius Kabi Nederland B.V. Postbus 2379 5202 CJ 's-Hertogenbosch Nederland Tel.: (31) 800 022 1905 Fax: (31) 0800 022 8295	Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	100 mg/50 ml
Czech Republic		Fresenius Kabi Nederland B.V. Postbus 2379 5202 CJ 's-Hertogenbosch Nederland Tel.: (31) 800 022 1905 Fax: (31) 0800 022 8295	Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml

Member State	Marketing Authorisation Holder	Applicant	Name	Strength	Pharmaceutical Form	Route of administration	Content (concentration)
Czech Republic		Fresenius Kabi Nederland B.V. Postbus 2379 5202 CJ 's-Hertogenbosch Nederland Tel.: (31) 800 022 1905 Fax: (31) 0800 022 8295	Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml
Germany		Fresenius Kabi Deutschland GmbH D-61346 Bad Homburg v.d.H. Tel.: (49) 6172 686-0 Fax: (49) 6172 686 73 32	Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	100 mg/50 ml
Germany		Fresenius Kabi Deutschland GmbH D-61346 Bad Homburg v.d.H. Tel.: (49) 6172 686-0 Fax: (49) 6172 686 73 32	Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml
Germany		Fresenius Kabi Deutschland GmbH D-61346 Bad Homburg v.d.H. Tel.: (49) 6172 686-0 Fax: (49) 6172 686 73 32	Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml
Denmark		Fresenius Kabi AB S-75174 Uppsala Tlf. nr (46) 18 644 000 Fax nr (46) 18 644 013	Ciprofloxacin Fresenius Kabi 2 mg/ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml, 400 mg/200 ml
Greece		Fresenius Kabi Hellas A.E. 354 Messogion Avenue GR-15341 Agia Paraskevi Attica Tel.: (30) 21 06 54 29 09 Fax: (30) 21 06 54 89 09	Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	100 mg/50 ml
Greece		Fresenius Kabi Hellas A.E. 354 Messogion Avenue GR-15341 Agia Paraskevi Attica Tel.: (30) 21 06 54 29 09 Fax: (30) 21 06 54 89 09	Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml
Greece		Fresenius Kabi Hellas A.E. 354 Messogion Avenue GR-15341 Agia Paraskevi Attica Tel.: (30) 21 06 54 29 09 Fax: (30) 21 06 54 89 09	Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml

Member State	Marketing Authorisation Holder	Applicant	Name	Strength	Pharmaceutical Form	Route of administration	Content (concentration)
Spain		Fresenius Kabi España S.A. c./ Marina 16-18, planta 17 E-08005 Barcelona Tel.: (0034-93) 225 65 80 Fax: (0034-93) 225 65 73	Ciprofloxacin Kabi 2 mg/ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml, 400 mg/200 ml
Finland		Fresenius Kabi AB S-75174 Uppsala Tlf nr: 0046 18 644 000 Fax nr: 0046 18 644 013	Ciprofloxacin Fresenius Kabi 2 mg/ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml, 400 mg/200 ml
Hungary		Fresenius Kabi Deutschland GmbH D-61346 Bad Homburg v.d.H. Tel.: (49) 6172 686-0 Fax: (49) 6172 686 73 32	Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml
Hungary		Fresenius Kabi Deutschland GmbH D-61346 Bad Homburg v.d.H. Tel.: (49) 6172 686-0 Fax: (49) 6172 686 73 32	Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml
Italy		Fresenius Kabi Italia S.r.L. via Camagre 41 I-37063 Isola della Scala (VR) Tel.: 0039 0456 64 93 11 Fax: 0039 0456 64 94 04	Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	100 mg/50 ml
Italy		Fresenius Kabi Italia S.r.L. via Camagre 41 I-37063 Isola della Scala (VR) Tel.: 0039 0456 64 93 11 Fax: 0039 0456 64 94 04	Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml
Italy		Fresenius Kabi Italia S.r.L. via Camagre 41 I-37063 Isola della Scala (VR) Tel.: 0039 0456 64 93 11 Fax: 0039 0456 64 94 04	Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml
Poland		Fresenius Kabi Deutschland GmbH D-61346 Bad Homburg v.d.H. Tel.: (49) 6172 686-0 Fax: (49) 6172 686 73 32	Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	100 mg/50 ml

Member State	Marketing Authorisation Holder	Applicant	Name	Strength	Pharmaceutical Form	Route of administration	Content (concentration)
Poland		Fresenius Kabi Deutschland GmbH D-61346 Bad Homburg v.d.H. Tel.: (49) 6172 686-0 Fax: (49) 6172 686 73 32	Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml
Poland		Fresenius Kabi Deutschland GmbH D-61346 Bad Homburg v.d.H. Tel.: (49) 6172 686-0 Fax: (49) 6172 686 73 32	Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml
Portugal		Fresenius Kabi Pharma Portugal Lda. Avenida do Forte 3 Edifício Suécia IV Piso 3 P-94-039 Carnaxide Tel.: (00351) 214 24 12 84 Fax: (00351) 214 24 12 90	Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	100 mg/50 ml
Portugal		Fresenius Kabi Pharma Portugal Lda. Avenida do Forte 3 Edifício Suécia IV Piso 3 P-794-039 Carnaxide Tel.: (00351) 214 24 12 84 Fax: (00351) 214 24 12 90	Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml
Portugal		Fresenius Kabi Pharma Portugal Lda. Avenida do Forte 3 Edifício Suécia IV Piso 3 P-94-039 Carnaxide Tel.: (00351) 214 24 12 84 Fax: (00351) 214 24 12 90	Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml
Sweden		Fresenius Kabi AB S-75174 Uppsala Tfn nr (46) 18 644 000 Fax nr (46) 18 644 013	Ciprofloxacin Fresenius Kabi 2 mg/ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml, 400 mg/200 ml
Slovak Republic		Fresenius Kabi Deutschland GmbH, D-61346 Bad Homburg v.d.H. Tel.: (49) 6172 686-0 Fax: (49) 6172 686 73 32	Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	100 mg/50 ml

Member State	Marketing Authorisation Holder	Applicant	Name	Strength	Pharmaceutical Form	Route of administration	Content (concentration)
Slovak Republic		Fresenius Kabi Deutschland GmbH D-61346 Bad Homburg v.d.H. Tel.: (49) 6172 686-0 Fax: (49) 6172 686 73 32	Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml
Slovak Republic		Fresenius Kabi Deutschland GmbH D-61346 Bad Homburg v.d.H. Tel.: (49) 6172 686-0 Fax: (49) 6172 686 73 32	Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml
United Kingdom		Fresenius Kabi Limited Cestrian Court Eastgate Way Manor Park Runcorn Cheshire WA7 1NT United Kingdom Tel.: (44-19) 28 59 42 21 Fax: (44-19) 28 59 43 14	Ciprofloxacine Kabi 100 mg/50 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	100 mg/50 ml
United Kingdom		Fresenius Kabi Limited Cestrian Court Eastgate Way Manor Park Runcorn Cheshire WA7 1NT United Kingdom Tel.: (44-19) 28 59 42 21 Fax: (44-19) 28 59 43 14	Ciprofloxacine Kabi 200 mg/100 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	200 mg/100 ml
United Kingdom		Fresenius Kabi Limited Cestrian Court Eastgate Way Manor Park Runcorn Cheshire WA7 1NT United Kingdom Tel.: (44-19) 28 59 42 21 Fax: (44-19) 28 59 43 14	Ciprofloxacine Kabi 400 mg/200 ml, solution for infusion	2 mg/ml	Solution for infusion	Intravenous use	400 mg/200 ml

NOTICES FROM MEMBER STATES

Publication of decisions by Member States to grant or revoke operating licenses pursuant to Article 13(4) of Council Regulation (EEC) No 2407/92 on licensing of air carriers [1] [2]

(Text with EEA relevance)

(2007/C 39/11)

GERMANY

Operating licences granted

Category B: Operating licences including the restriction of Article 5(7)(a) of Regulation (EEC) No 2407/92

Name of air carrier	Address of air carrier	Permitted to carry	Decision effective since
Air Hamburg Luftverkehrsgesellschaft mbH	Kleine Bahnstr. 8 D-22525 Hamburg	passengers, mail, cargo	13.12.2006
DVS Deutsche Verkehrsfliegerschule GmbH	Flugplatz D-63329 Egelsbach	passengers, mail, cargo	31.1.2007

Operating licences revoked

Category A: Operating licences without the restriction of Article 5(7)(a) of Regulation (EEC) No 2407/92

Name of air carrier	Address of air carrier	Permitted to carry	Decision effective since
Lufthansa Flight Training GmbH	Airporting Tor 24 D-60549 Frankfurt/Main	passengers, mail, cargo	22.12.2006
Antares Airtransport Maintenance und Service AG	Friedenstr. 113 D-02929 Rothenburg/Oberlausitz	passengers, mail, cargo	31.1.2007

Category B: Operating licences including the restriction of Article 5(7)(a) of Regulation (EEC) No 2407/92

Name of air carrier	Address of air carrier	Permitted to carry	Decision effective since
Helicopter Medical Services	Flugplatz D-63329 Egelsbach	passengers, mail, cargo	21.12.2006

[1] OJ L 240, 24.8.1992, p.1.
[2] Communicated to the European Commission before 31.8.2005.

V

(Announcements)

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMMON COMMERCIAL POLICY

COMMISSION

Notice of initiation of a partial interim review of the antidumping measures applicable to imports of grain oriented flat-rolled products of silicon-electrical steel (GOES) originating in Russia

(2007/C 39/12)

The Commission has decided on its own initiative to initiate a partial interim review pursuant to Article 11(3) of Council Regulation (EC) No 384/96 on protection against dumped imports from countries not members of the European Community ('the basic Regulation') ([1]). The review is limited to the examination of the level of dumping for two Russian exporting producers, Novolipetsk Iron & Steel Corporation (NLMK) and Viz Stal.

1. **Product**

The product under review is grain oriented flat-rolled products of silicon-electrical steel originating in Russia ('the product concerned'), currently classifiable within CN codes 7225 11 00 and 7226 11 00. These CN codes are given only for information.

2. **Existing measures**

The measures currently in force are a definitive anti-dumping duty imposed by Council Regulation (EC) No 1371/2005 ([2]) on imports of grain oriented flat-rolled products of silicon-electrical steel originating in Russia. By Decision No 2005/622/EC of 5 August 2005 ([3]), the Commission accepted an undertaking offered by Novolipetsk Iron & Steel Corporation. As a result, imports of the product concerned from this company are not subject to the definitive anti-dumping duty in accordance with Article 2 of Regulation (EC) No 1371/2005.

3. **Grounds for the review**

The Commission has been notified that NLMK has acquired 100 % of Viz Stal. In addition, evidence has been provided regarding production, sales and distribution of the product concerned under the new corporate structure. In view of this evidence, the circumstances on the basis of which measures were established appear to have changed in a lasting way.

The evidence at hand also shows that the dumping margin under the new corporate structure would change significantly as compared to the level of the current measures.

On the basis of the foregoing, it appears that the individual duties in force for NLMK (although duties are currently not collected for imports from this company for the reason set out in point 2 above) and Viz Stal are no longer appropriate, and that a review should be initiated *ex officio* in order to calculate one single measure for the new joint company.

4. **Procedure for the determination of dumping**

(a) *General*

Having determined, after consulting the Advisory Committee, that sufficient evidence exists to justify the initiation of a partial interim review, the Commission hereby initiates a review in accordance with Article 11 (3) of the basic Regulation.

The investigation will assess the need for the continuation, removal or amendment of the existing measures in respect of NLMK and Viz Stal under the new corporate structure. This assessment will be made on the basis of data collected during the investigation that lead to the imposition of the existing measures.

([1]) OJ L 56, 6.3.1996, p. 1. Regulation as last amended by Regulation (EC) No 2117/2005 (OJ L 340, 23.12.2005, p. 17.).
([2]) OJ L 223, 27.8.2005, p. 1.
([3]) OJ L 223, 27.8.2005, p. 42.

If it is determined that measures should be removed or amended for the companies concerned by this review under the new corporate structure, it may be necessary to amend the rate of duty currently applicable to imports from other exporting producers of the product concerned as set out in Article 1(2) of Council Regulation (EC) No 1371/2005.

(b) *Collection of information and holding of hearings*

All interested parties are hereby invited to make their views known, submit information and to provide supporting evidence. This information and supporting evidence must reach the Commission within the time limit set in point 6 (a).

Furthermore, the Commission may hear interested parties, provided that they make a request showing that there are particular reasons why they should be heard. This request must be made within the time limit set in point 6(b).

5. **Time limits**

(a) *For parties to make themselves known and to submit any other information*

All interested parties, if their representations are to be taken into account during the investigation, must make themselves known by contacting the Commission, present their views and submit any other information within 40 days of the date of publication of this notice in the *Official Journal of the European Union*, unless otherwise specified. Attention is drawn to the fact that the exercise of most procedural rights set out in the basic Regulation depends on the party's making itself known within the aforementioned period.

(b) *Hearings*

All interested parties may also apply to be heard by the Commission within the same 40-day time limit.

6. **Written submissions and correspondence**

All submissions and requests made by interested parties must be made in writing (not in electronic format, unless otherwise specified) and must indicate the name, address, e-mail address, telephone and fax numbers of the interested party. All written submissions, including the information requested in this notice and correspondence provided by interested parties on a confidential basis shall be labelled as *'Limited* [1]' and, in accordance with Article 19(2) of the basic Regulation, shall be accompanied by a non-confidential version, which will be labelled 'FOR INSPECTION BY INTERESTED PARTIES'.

Commission address for correspondence:

European Commission
Directorate General for Trade
Directorate B
Office: J-79 5/16
B-1049 Brussels
Fax: (32-2) 295 65 05

7. **Non-co-operation**

In cases in which any interested party refuses access to or does not provide the necessary information within the time limits, or significantly impedes the investigation, findings, affirmative or negative, may be made in accordance with Article 18 of the basic Regulation, on the basis of the facts available.

Where it is found that any interested party has supplied false or misleading information, the information shall be disregarded and use may be made, in accordance with Article 18 of the basic Regulation, of the facts available. If an interested party does not cooperate or cooperates only partially, and use of facts available is made, the result may be less favourable to that party than if it had cooperated.

8. **Schedule of the investigation**

The investigation will be concluded, according to Article 6(9) of the basic Regulation within 15 months of the date of the publication of this notice in the *Official Journal of the European Union*.

[1] This means that the document is for internal use only. It is protected pursuant to Article 4 of Regulation (EC) No 1049/2001 of the European Parliament and of the Council regarding public access to European Parliament, Council and Commission documents (OJ L 145, 31.5.2001, p. 43). It is a confidential document pursuant to Article 19 of the basic Regulation and Article 6 of the WTO Agreement on Implementation of Article VI of the GATT 1994 (Anti-dumping Agreement).

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY

COMMISSION

Prior notification of a concentration

(Case COMP/M.4469 — Scholz/voestalpine/Scholz Austria)

(Text with EEA relevance)

(2007/C 39/13)

1. On 15 February 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [1] by which the undertakings Scholz AG ('Scholz', Germany) and voestalpine AG ('voestalpine', Austria) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of Scholz Austria GmbH ('Scholz Austria', Austria) by means of purchase of shares in a newly created company constituting a joint venture.

2. The business activities of the undertakings concerned are:

— for Scholz: collection and processing of and trade in metal scrap;

— for voestalpine: production and processing of steel products;

— for Scholz Austria: collection and processing of and trade in metal scrap.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax No (32-2) 296 43 01 or 296 72 44) or by post, under reference number Case COMP/M.4469 — Scholz/voestalpine/Scholz Austria, to the following address:

European Commission
Directorate-General for Competition
Merger Registry
J-70
B-1049 Bruxelles/Brussel

[1] OJ L 24, 29.1.2004, p. 1.

Prior notification of a concentration

(Case COMP/M.4522 — Carrefour/Ahold Polska)

(Text with EEA relevance)

(2007/C 39/14)

1. On 16 February 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ([1]) by which the undertaking Carrefour Nederland BV ('Carrefour Nederland', Netherlands), belonging to the group Carrefour ('Carrefour', France), acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Ahold Polska Sp. z o.o ('Ahold Polska', Poland) by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— for Carrefour: international group active in food and non-food retailing;

— for Ahold Polska: part of the Ahold group, active in food and non-food retailing in Poland.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4522 — Carrefour/Ahold Polska, to the following address:

European Commission
Directorate-General for Competition
Merger Registry
J-70
B-1049 Bruxelles/Brussel

([1]) OJ L 24, 29.1.2004, p. 1.

NOTICE

On 23 February 2007, in *Official Journal of the European Union* C 39 A, the 'Common catalogue of agricultural plant species —25th complete edition' will be published.

Subscribers to the Official Journal may obtain the same number of copies and language versions of this Official Journal as those to which they subscribe free of charge. They are requested to return the attached order form, duly completed and bearing their subscription registration number (code appearing on the left of each label and beginning with: O/…). This Official Journal will remain available free of charge for one year from the date of its publication.

Non-subscribers can order this Official Journal against payment from one of our sales offices (see http://publications.europa.eu/others/sales_agents_en.html).

This Official Journal — like all Official Journals (L,C,CA,CE) — can be consulted free of charge online at http://eur-lex.europa.eu.

ORDER FORM

Office for Official Publications
of the European Communities
Subscription Department
2, rue Mercier
L-2985 Luxembourg
Fax (352) 29 29-42752

My registration number is as follows: O/……

Please send me … free copy/copies of **Official Journal C 39 A/2007** to which I am entitled by my subscription/s.

Name: .....

Address: .....

.....

Date: ..... Signature: .....